Avantis International Small Cap Value ETF vs GeneDx Holdings Corp — how do they compare? Avantis International Small Cap Value ETF trades at $105.24, while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| AVDV | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $110.40 | $167.51 |
52-Week Low | $80.02 | $34.51 |
Market Cap | — | $1.85B |
Enterprise Value | — | $1.85B |
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $103.10, down 1.06% with a bearish technical signal from moving averages. Recent news highlights strong 2026 performance with international small-cap value strategies delivering 35% gains while paying dividends. The fund's commodity exposure has cooled after driving outperformance, shifting the forward setup.
The outlook remains mixed with technical indicators signaling caution but positive sentiment around international small-cap value diversification. Key risks include commodity volatility and regional economic exposure, while institutional interest grows with Farther Finance increasing holdings by 165.8% in Q4 2025.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Trailing returns across standard periods
Latest headlines on both assets
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →